Related Overviews


'anti-RNA' can also refer to...


Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies

Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference

The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription

Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase

Non-inhibited miRNAs shape the cellular response to anti-miR

E43 Anti-Transfer RNA Synthetase Syndrome Presenting as Cryptogenic Organising Pneumonia

Anti-prion activity of an RNA aptamer and its structural basis

DNA mimicry by a high-affinity anti-NF-κB RNA aptamer

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA

A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis

Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay

Bacteriophage Xp10 anti-termination factor p7 induces forward translocation by host RNA polymerase

Thorough validation of siRNA-induced cell death phenotypes defines new anti-apoptotic protein

Prevalence of hepatitis G virus RNA and anti-E2 in a Japanese haemodialysis population.

Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies

Scleroderma-like renal crisis in a patient with anti-threonyl-tRNA synthetase-associated antisynthetase syndrome

Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia


More Like This

Show all results sharing this subject:

  • Chemistry


Show Summary Details

Quick Reference

Single‐stranded RNA complementary to mRNA. See antisense RNA.

Subjects: Chemistry.

Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.